Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Document › Details

AC Immune S.A.. (3/23/17). "Press Release: AC Immune Provides Twelve Update on Its Pipeline". Lausanne.

Organisations Organisation AC Immune S.A. (Nasdaq: ACIU)
  Organisation 2 Piramal (Group)
Products Product Alzheimer drug
  Product 2 Alzheimer test
Index terms Index term Roche–AC Immune: therapeutic antibodies, 201206– license excl for anti-Tau program for Alzheimer’s disease to Genentech
  Index term 2 Nestlé–AC Immune: Alzheimer test, 201509– collab r+d minimally invasive Tau Dx assay Néstle Institute of Health Sciences
Person Person Schier, Eva (AC Immune 201605 Corporate Communciations Manager)
     


AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that twelve updates on the advancement of its product and partnered product candidates and R&D programs will be provided/presented at the 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM 2017). The conference is taking place in Vienna, Austria from March 29th to April 2nd, 2017.


Program and Collaborator
> Presentations and Timing


Crenezumab /
Genentech

> Long term safety of crenezumab in an open-label extension of Phase 2 studies in mild-to moderate AD
Poster - March 30 
> Long term safety and tolerability of escalating doses of crenezumab in patients with mild-to-moderate Alzheimer's disease
Oral Presentation - March 31 / 10:30-10:45
> Crenezumab's preferential binding of oligomeric amyloid-beta species underlies its unique mechanism of action
Poster - April 1


anti-Tau antibody /
Genentech

> A Phase 1 study to evaluate the safety and tolerability of RO7105705 in healthy volunteers and patients with mild-to-moderate AD
Poster - March 29
> Preclinical characterization, efficacy, pharmacokinetics and pharmacodynamics and safety of RO7105705 - an anti-Tau antibody currently in clinical development for AD
Oral presentation - March 29 / 10:00-10:15
> Chronic treatment with the murine surrogate of anti-Tau antibody RO7105705 reduces Tau pathology in a transgenic mouse model of tauopathy
Poster - March 29


Tau-PET imaging agent /
Piramal

> First in human characterization of PI-2620, a next generation PET tracer for assessing tau in AD and other tauopathies
Poster - March 29
> Characterization of novel PET tracers for the assessment of Tau pathology in AD and other tauopathies
Oral presentation - March 31 / 16:15-16:30


alpha-syn-PET imaging agent / Biogen

> Novel PET Tracers of alpha-Synuclein for the
diagnosis of Parkinson's Disease
Oral presentation - March 31 / 16:30-16:45


Morphomer Tau

> Small molecules targeting Tau propagation demonstrate efficacy in an aggressive tauopathy mouse model
Oral presentation - April 1 / 15:30-15:45


Tau spreading /
École Polytechnique Fédérale de Lausanne (EPFL)

> The frequency of tau propagation from neuron to neuron is increased in mice carrying the amyloid pathology
Poster - March 29


Abeta and Tau molecular profiling /
Nestlé Institute of Health Sciences (NIHS)

> A new tool for the profiling of Tau and Abeta in AD
Poster - March 29


Selected presentations and posters will be made available at the conclusion of the AD/PDTM 2017 Conference on AC Immune's website under the section Science.


Forward looking statements


This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information-Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission.  Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.


For further information please contact:

Prof. Andrea Pfeifer

Chief Executive Officer

Phone: +41 21 345 91 21

E-mail: andrea.pfeifer@acimmune.com

Eva Schier

Corporate Communications Manager

Phone: +41 21 345 91 34

Mobile: +41 79 926 66 03

E-mail: eva.schier@acimmune.com

 

Nick Miles/Toomas Kull

Cabinet Privé de Conseils s.a.

Phone: +41 22 321 45 40

E-mail: miles@cpc-pr.com
   
kull@cpc-pr.com

 

In the US

Ted Agne

The Communications Strategy Group Inc.

Phone: +1 781 631 3117

E-mail: edagne@comstratgroup.com

   
Record changed: 2019-06-09

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for AC Immune S.A. (Nasdaq: ACIU)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Open BEU2019 650x80px




» top